POLB announced today announces that the opposition to one of its European patents (Immunomodulator I) that was filed by a third party is to be withdrawn. In the pharmaceutical industry it is not unusual for patents to be challenged. POLB had previously disclosed in September 2021 that the Immunomodulator I European patent had been opposed but this has now been resolved. We maintain our BUY recommendation and 21p PT.

19 Sep 2023
Patent opposition withdrawn

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Patent opposition withdrawn
Poolbeg Pharma PLC (POLB:LON) | 9.3 0 (-0.5%) | Mkt Cap: 46.5m
- Published:
19 Sep 2023 -
Author:
Karl Keegan -
Pages:
3 -
POLB announced today announces that the opposition to one of its European patents (Immunomodulator I) that was filed by a third party is to be withdrawn. In the pharmaceutical industry it is not unusual for patents to be challenged. POLB had previously disclosed in September 2021 that the Immunomodulator I European patent had been opposed but this has now been resolved. We maintain our BUY recommendation and 21p PT.